# High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

> **NCT03991130** · PHASE2 · TERMINATED · sponsor: **Gregory Daniels** · enrollment: 6 (actual)

## Conditions studied

- Melanoma Stage Iv
- Renal Cell Carcinoma, Metastatic

## Interventions

- **DRUG:** IL-2 and Nivolumab

## Key facts

- **NCT ID:** NCT03991130
- **Lead sponsor:** Gregory Daniels
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-23
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991130, "High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03991130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*